{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:54:55Z","timestamp":1792608895665,"version":"4.5.0"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"54","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,3]]},"DOI":"10.18632\/oncotarget.19279","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T09:55:19Z","timestamp":1500285319000},"page":"91841-91859","source":"Crossref","is-referenced-by-count":34,"title":["Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism"],"prefix":"10.18632","volume":"8","author":[{"given":"Claudia","family":"Fumarola","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cretella","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Monica","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara A.","family":"Bonelli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Caffarra","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Falco","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavazzoni","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana","family":"Digiacomo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mazzaschi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vivo","sequence":"additional","affiliation":[{"name":"Food and Drug Department, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Barocelli","sequence":"additional","affiliation":[{"name":"Food and Drug Department, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Petronini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Grose","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Smith","year":"2012","journal-title":"Clin Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1158\/0008-5472.CAN-13-2469","article-title":"Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation","volume":"74","author":"Schwertfeger","year":"2014","journal-title":"Cancer Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccr.2007.11.004","article-title":"Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition","volume":"12","author":"Spencer","year":"2007","journal-title":"Cancer Cell"},{"key":"5","doi-asserted-by":"crossref","first-page":"e38972","DOI":"10.1371\/journal.pone.0038972","article-title":"FGFR1-induced epithelial to mesenchymal transition through MAPK\/PLCgamma\/COX-2-mediated mechanisms","volume":"7","author":"Knowles","year":"2012","journal-title":"PLoS One"},{"key":"6","first-page":"ra73","article-title":"Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth","volume":"2","author":"Polakiewicz","year":"2009","journal-title":"Sci Signal"},{"key":"7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.molcel.2011.10.015","article-title":"Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism","volume":"44","author":"Lonial","year":"2011","journal-title":"Mol Cell"},{"key":"8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Gainor","year":"2015","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"de Castro","year":"2016","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Polikoff","year":"2017","journal-title":"Lancet"},{"key":"12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ctrv.2015.04.011","article-title":"FGFR as potential target in the treatment of squamous non small cell lung cancer","volume":"41","author":"Ardizzoni","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"13","first-page":"62ra93","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Fischer","year":"2010","journal-title":"Sci Transl Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"e20351","DOI":"10.1371\/journal.pone.0020351","article-title":"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer","volume":"6","author":"Meyerson","year":"2011","journal-title":"PLoS One"},{"key":"15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Kurzrock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-12-0999","article-title":"Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells","volume":"12","author":"Galderisi","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wojtylak","year":"2014","journal-title":"Clin Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/0008-5472.CAN-08-4327","article-title":"Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors","volume":"69","author":"Ulkus","year":"2009","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/onc.2015.426","article-title":"Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression","volume":"35","author":"Yano","year":"2016","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CAD.0000000000000034","article-title":"Essential role of AKT in tumor cells addicted to FGFR","volume":"25","author":"Chai","year":"2014","journal-title":"Anticancer Drugs"},{"key":"21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","article-title":"AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo","volume":"17","author":"DeBerardinis","year":"2013","journal-title":"Cell Metab"},{"key":"22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-013-2668-x","article-title":"Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling","volume":"141","author":"Bonelli","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"23","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","article-title":"Akt stimulates aerobic glycolysis in cancer cells","volume":"64","author":"Thompson","year":"2004","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"Thompson","year":"2008","journal-title":"Cell Metab"},{"key":"25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semcancer.2008.11.010","article-title":"Is Akt the \u201cWarburg kinase\u201d?-Akt-energy metabolism interactions and oncogenesis","volume":"19","author":"Hay","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","article-title":"HIF-1: upstream and downstream of cancer metabolism","volume":"20","author":"Semenza","year":"2010","journal-title":"Curr Opin Genet Dev"},{"key":"27","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1038\/sj.onc.1204972","article-title":"Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras\/MAP kinase mediated signaling pathways","volume":"20","author":"Theodorescu","year":"2001","journal-title":"Oncogene"},{"key":"28","doi-asserted-by":"crossref","first-page":"32631","DOI":"10.1074\/jbc.274.46.32631","article-title":"p42\/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1","volume":"274","author":"Pouyssegur","year":"1999","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Semenza","year":"2011","journal-title":"Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4161\/cbt.5.7.2972","article-title":"Translational control of gene expression during hypoxia","volume":"5","author":"Wouters","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"31","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2005-09-3541","article-title":"Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells","volume":"107","author":"Melillo","year":"2006","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"e3078","DOI":"10.1371\/journal.pone.0003078","article-title":"FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha","volume":"3","author":"Prats","year":"2008","journal-title":"PLoS One"},{"key":"33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.15252\/emmm.201404271","article-title":"Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality","volume":"7","author":"Harris","year":"2015","journal-title":"EMBO Mol Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","article-title":"Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398","volume":"16","author":"Roychowdhury","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/annonc\/mdn048","article-title":"Src as a potential therapeutic target in non-small-cell lung cancer","volume":"19","author":"Zucali","year":"2008","journal-title":"Ann Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/onc.2015.256","article-title":"Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis","volume":"35","author":"Hochwald","year":"2016","journal-title":"Oncogene"},{"key":"37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2012.03.034","article-title":"Overcoming acquired resistance to letrozole by targeting the PI3K\/AKT\/mTOR pathway in breast cancer cell clones","volume":"323","author":"Andreis","year":"2012","journal-title":"Cancer Lett"},{"key":"38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-009-0714-5","article-title":"Synergistic activity of letrozole and sorafenib on breast cancer cells","volume":"124","author":"Martin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"39","doi-asserted-by":"crossref","first-page":"e78656","DOI":"10.1371\/journal.pone.0078656","article-title":"Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification","volume":"8","author":"Ardizzoni","year":"2013","journal-title":"PLoS One"},{"key":"40","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1535-7163.MCT-14-0892","article-title":"Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations","volume":"14","author":"Falco","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jtho.2016.03.006","article-title":"Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation","volume":"11","author":"Naldi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"e0141795","DOI":"10.1371\/journal.pone.0141795","article-title":"Effect of ABCG2\/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines","volume":"10","author":"Alfieri","year":"2015","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/bj1260525","article-title":"The pentose cycle and insulin release in mouse pancreatic islets","volume":"126","author":"Randle","year":"1972","journal-title":"Biochem J"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:39:47Z","timestamp":1596735587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":43,"journal-issue":{"issue":"54","published-print":{"date-parts":[[2017,11,3]]}},"alternative-id":["19279","29190880"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19279","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}